COMPARISON OF HAND-REARED PRONGHORN () MILK REPLACER COMPOSITIONS AND GROWTH RATES.

Hand-rearing protocols for nondomestic ungulates used for research, zoological parks, and reintroduction to the wild are evaluated on the basis of implementation practicality, gastrointestinal disturbances, survival to weaning, and growth rates compared with those of dam-raised individuals. Although species-specific protocols utilizing milk replacers formulated for nondomestic ungulates have been reported, no such protocols have been published for pronghorn (Antilocapra americana). Five pronghorn fawns were fed Day One 30/40 Black Tail Deer plus Lactobacillus acidophilus probiotics four times per day with Day One Ultra Boost (all products from Fox Valley Animal Nutrition, Inc, Huntley, IL 60142, USA) added at one feeding per day and weighed twice per week for up to the first 16 wk of life.

Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer.

Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is prognostic of poor survival for patients with non-small cell lung cancer (NSCLC). KRAS G12C mutations occur in 13% of NSCLC cases and despite the frequency of this mutation, advances in drug development against KRAS have historically been impeded due to the extremely high affinity of KRAS for guanosine triphosphate (GTP) and the lack of a binding pocket on the surface of KRAS that is suitable for drug binding. Sotorasib, a first-in-class, highly selective KRAS G12C inhibitor overcomes this issue by irreversibly binding in the switch-II pocket.

Safety and Tolerability of Letetresgene Autoleucel (Lete-cel; GSK3377794): Pilot Studies in Patients With Advanced Non-Small Cell Lung Cancer.

Purpose: To evaluate safety, tolerability, and anti-tumor response of lete-cel, genetically modified autologous T-cells expressing a T-cell receptor specific for NY-ESO-1/LAGE-1a shared epitope, alone or in combination with pembrolizumab, in human leukocyte antigen HLA-A*02-positive (HLA-A*02:01-, HLA-A*02:05-, and/or HLA-A*02:06-) patients with New York esophageal squamous cell carcinoma 1 (NY-ESO-1)- and/or LAGE-1a-positive non-small cell lung cancer (NSCLC).

Experimental Design: Study 208749 was a single-arm study of lete-cel alone. Study 208471 was a multi-arm study of lete-cel alone or in combination with pembrolizumab in patients with advanced or recurrent NSCLC.

Can we trust the data? - the data detective.

Despite the title and content of my talk, I am optimistic for the future of healthcare research. I will return to that sense of optimism in my conclusion. But to cheer you up at the end of my talk I first must depress you.